Clinical Trials Logo

Age-Related Macular Degeneration clinical trials

View clinical trials related to Age-Related Macular Degeneration.

Filter by:

NCT ID: NCT00556114 Completed - Glaucoma Clinical Trials

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

Start date: January 2007
Phase:
Study type: Observational

Growing evidence shows that altered blood flow plays a major role in many vision-threatening diseases including glaucoma, diabetic retinopathy, age-related macular degeneration, Central Retinal Vein Occlusion, and Branch Retinal Vein Occlusion. Optical coherence tomography, an established imaging technique use for eye exam in clinical ophthalmology, provides high-resolution cross sectional images of the retina and has increased our ability to understand many eye diseases.

NCT ID: NCT00539734 Completed - Clinical trials for Age-related Macular Degeneration

Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration

Start date: August 2007
Phase: N/A
Study type: Interventional

Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits the growth of new vessels and has recently been approved by FDA for treating this condition. This study is carried out to evaluate the changes in retinal function after an injection of ranibizumab.

NCT ID: NCT00527553 Completed - Clinical trials for Age-related Macular Degeneration

The Effect of Eggs and Egg Products on Macular Pigment

Start date: October 2007
Phase: N/A
Study type: Interventional

Age-related macula degeneration (AMD, encompassing both dry and wet form), the late stage of Age-related maculopathy (ARM), is the leading cause of blindness in many developed countries in older persons (usually over 60 years of age). Visual compromise rises exponentially after the age of 70 with a 5-year incidence of around 1%. Studies have shown a possible protective effect of lutein on progression of AMD, where visual acuity improves after increased lutein intake. The incidence of bilateral AMD in persons with unilateral late ARM observed over a period of 10 years is over 50% with a 2.1-2.8% overall incidence in the study population. Blue light hazard (excitation peak 440 nm) was shown to have a major impact on photoreceptor and RPE function inducing photochemical damage and cellular apoptosis, leading to retinal degeneration in an animal study. The current belief is that lutein accumulated in the macular region helps in the prevention of blindness by absorbing blue light and protecting the retina from oxidative stress. With the lipid matrix of the egg yolk being a proven vehicle for the efficient absorption of dietary lutein, it might be possible to increase plasma levels of lutein to therapeutic levels and control or prevent AMD. This, the investigators hope, will be accomplished by means of filtering out harmful blue light and the scavenging of free radicals by lutein and zeaxanthin.

NCT ID: NCT00517010 Completed - Clinical trials for Age-Related Macular Degeneration

Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration

Start date: May 2007
Phase: Phase 0
Study type: Interventional

Because a possible synergism of radiation and inhibitors of vascular endothelial growth factor has been shown in cancer patients and patients with wet macular degeneration, this pilot study is being conducted to determine whether treating wet macular degeneration with a combination of Lucentis and proton beam irradiation is safe. Lucentis is an inhibitor of vascular endothelial growth factor which was recently FDA approved for treatment of wet macular degeneration. It appears to be the most effective therapy thus far for wet macular degeneration among all drugs FDA approved for this condition. If no major safety issues are associated with this combination therapy, a larger study will be conducted to determine whether this combination therapy is more effective than Lucentis monotherapy. l

NCT ID: NCT00500344 Completed - Clinical trials for Age-related Macular Degeneration

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

CAPTAIN
Start date: July 2007
Phase: Phase 1
Study type: Interventional

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD

NCT ID: NCT00473928 Completed - Clinical trials for Age-Related Macular Degeneration

Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

ASaP
Start date: May 2007
Phase: Phase 1
Study type: Interventional

The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD

NCT ID: NCT00470678 Completed - Clinical trials for Age-Related Macular Degeneration

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Start date: June 2007
Phase: Phase 3
Study type: Interventional

This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

NCT ID: NCT00463320 Completed - Clinical trials for Age-related Macular Degeneration

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

Start date: March 2007
Phase: Phase 1
Study type: Interventional

This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.

NCT ID: NCT00446654 Completed - Clinical trials for Age Related Macular Degeneration

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Start date: April 2007
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.

NCT ID: NCT00429962 Completed - Clinical trials for Age-Related Macular Degeneration

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Start date: July 2006
Phase: Phase 3
Study type: Interventional

This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal CNV secondary to AMD